Positive effects of magnesium supplementation in metabolic syndrome.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Who Took Part

The abstract describes 27 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

In this context, the researchers conducted a prospective, randomized, double-blind study on serum and ionized magnesium, systolic and diastolic blood pressure values, interleukin-6, vitamin D, and metabolic profile in 27 patients (13 male/14 female, age: 60.2 ± 12.5 years) with metabolic syndrome.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the patients nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

What Was Measured

Topics PubMed links to this paper include Metabolic Syndrome, Dietary Supplements, Magnesium, Interleukin-6, Blood Pressure, Vitamin D and Biomarkers.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc in 27 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 14 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (International journal of clinical pharmacology and therapeutics), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.